Prolonged Prophylaxis in Orthopedic Surgery: Insights from the United States

ABSTRACT

The U.S. Hip and Knee Registry is a voluntary national registry of outcome data for hip and knee surgery. In total, 469 orthopedic surgeons from 325 hospitals reported data on 7677 patients who underwent total hip arthroplasty (THA) and 11,461 patients who underwent total knee arthroplasty (TKA). Data on patients enrolled between 1996 and 2000 indicate that 40% of THA patients and 42% of TKA patients received prophylaxis for a period of 8 to 21 days, including the in-hospital period. Prolonged prophylaxis for more than 21 days was used in 49% of THA patients and 44% of TKA patients. Moreover, year on year, data indicate that the percentage of patients who receive prophylaxis for longer than 21 days is gradually increasing. In 2000, 53% of THA patients and 47% of TKA patients received prophylaxis for longer than 21 days.

KEYWORDS

Orthopedic surgeons - total hip arthroplasty - total knee arthroplasty - thromboprophylaxis - prolonged prophylaxis

REFERENCES

• 1 Geerts W H, Heit J A, Clagett P. Prevention of venous thromboembolism.  Chest . 2001;  119 132S-175S
• 2 Huber O, Bounameaux H, Borst F, Rohner A. Postoperative pulmonary embolism after hospital discharge. An underestimated risk.  Arch Surg . 1992;  127 310-313
• 3 Planes A, Vochelle N, Darmon J Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comprison of enoxaparin versus placebo.  Lancet . 1996;  348 224-228
• 4 Bergqvist D, Benoni G, Bjorgell O. Low-molecular-weight heparin (enoxaparin) as prophylaxis against thromboembolism after total hip replacement.  N Engl J Med . 1996;  335 696-700
• 5 Dahl O E, Andreassen G, Aspelin T. Prolonged prophylaxis following hip replacement surgery-results of a double-blind, prospective, randomised placebo-controlled study with dalteparin (Fragmin).  Thromb Haemost . 1997;  77 26-31
• 6 Lassen M R, Borris L C, Anderson B S. Efficacy and safety of prolonged prophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty-The Danish Prolonged Prophylaxis (DaPP) Study.  Thromb Res . 1998;  89 281-287
• 7 Hull R D, Pineo G F, for the NAFT Investigators. A double-blind randomised comparison of extended out-of-hospital prophylaxis using dalteparin versus placebo in patients undergoing elective hip replacement.  Thromb Haemost . 1999;  17(Suppl) 6(Abst)
• 8 Cohen A T, Krushal A. Extended thromboprophylaxis following lower limb arthroplasty: what do the clinical trials mean?.  Haemostasis . 2000;  30(Suppl 2) 88-94
• 9 Comp P C, Spiro T E, Friedman R J. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.  J Bone Joint Surg Am . 2001;  83-A 336-345